Iseganan: IBPI completed enrollment of 509 patients in its U.S. Phase III trial of iseganan to reduce the incidence and severity of ulcerative oral mucositis in

IntraBiotics Pharmaceuticals Inc. (IBPI), Mountain View, Calif.
Product: Iseganan (formerly protegrin) oral rinse

Read the full 133 word article

How to gain access

Continue reading with a
two-week free trial.